Medical Condition News

RSS

UC Berkeley study finds self-worth key to diagnoses of psychopathologies

Donald Trump's ego may be the size of his financial empire, but that doesn't mean he's the picture of mental health. The same can be said about the self-esteem of people who are living from paycheck to paycheck, or unemployed. New research from the University of California, Berkeley, underscores this mind-wallet connection.

8 Dec 2014

Spark Therapeutics, Pfizer partner to develop SPK-FIX for potential treatment of hemophilia B

Spark Therapeutics, a late-stage gene therapy company developing treatments for debilitating genetic diseases, announced today that it has entered into a global collaboration with Pfizer Inc. for the development and potential commercialization of SPK-FIX, a development program advancing proprietary, bio-engineered adeno-associated virus (AAV) vectors for the potential treatment of hemophilia B.

8 Dec 2014

Henry Ford Hospital recruits patients to participate in brain cancer clinical trial

Henry Ford Hospital today announced that it is actively recruiting patients to participate in a clinical trial taking place at the Hermelin Brain Tumor Center which is showing promising results in patients with brain cancer.

8 Dec 2014

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.

8 Dec 2014

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase I clinical trial assessing the safety and efficacy of escalating doses of CPI-613, in combination with bendamustine and rituximab, in patients with relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL).

8 Dec 2014

New fluorescence-imaging agent could improve diagnosis, guide surgeons during tumor removal

CEA-Leti and CLARA today announced the development of a new fluorescence-imaging agent that could significantly increase surgeons’ accuracy when removing cancerous tumors.

8 Dec 2014

Daiichi Sankyo releases new formulation of LIXIANA 60 mg Tablets

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new formulation of LIXIANA 60 mg Tablets (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban, approval to market: September 26, 2014; NHI drug price listing: November 25, 2014) in Japan for the recently approved indications: the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and the treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism (PE)].

8 Dec 2014

Researchers report promising outcomes from clinical trial in patients with dyskeratosis congenita

Researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center report promising outcomes from a clinical trial with patients with a rare form of bone marrow failure who received a hematopoietic stem cell transplant (HSCT) after pre-treatment with immunosuppressive drugs only. This is the first trial reporting successful transplant in dyskeratosis congenita (DC) patients without the use of any radiation or conventional cytotoxic chemotherapy beforehand.

8 Dec 2014

Scientists discover new line of defence that cancer cells use to evade cell death

Cancer Research UK scientists have discovered a new line of defence used by cancer cells to evade cell death, according to research published in Nature Communications today (Monday).

8 Dec 2014

New advancement in biomedical research could help tackle diseases associated with ageing

A new advance in biomedical research at the University of Leicester could have potential in the future to assist with tackling diseases and conditions associated with ageing - as well as in treating cancer.

8 Dec 2014

Vitamin C may reduce exercise-induced bronchoconstriction and respiratory symptoms

Physical activity increases oxidative stress, and therefore, as an antioxidant vitamin C might have particularly evident effects on people who are participating in vigorous exercise. In several studies, vitamin C administration attenuated the increases in oxidative stress markers caused by exercise. Furthermore, vitamin C is involved in the metabolism of histamine, prostaglandins, and cysteinyl leukotrienes, all of which appear to be mediators in the pathogenesis of exercise-induced bronchoconstriction.

8 Dec 2014

Combination therapy benefits patients with acute myeloid leukemia

Patients who relapse in their battle with acute myeloid leukemia (AML) may benefit from a phase three study of therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin.

8 Dec 2014

iTeos Therapeutics, Pfizer form strategic collaboration for cancer immunotherapeutics

iTeos Therapeutics SA announced today a strategic collaboration with Pfizer Inc. pursuant to which iTeos will license to Pfizer rights to iTeos' pre-clinical compounds targeting Indoleamine 2,3-dioxygenase (IDO1) and Tryptophan 2,3-dioxygenase (TDO2). Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates.

8 Dec 2014

Researchers gain new insights into potential treatment for Alzheimer's disease

It is estimated that about 35 million people worldwide currently suffer from dementia and it is expected that the number will increase to 135 million by the year 2050. The disease is already one of the most common health problems in the elderly, which is why experts predict that the numbers of people affected will increase over time.

8 Dec 2014

Subsets of cells drive spread of multiple myeloma

Although it is among the most highly metastatic of all cancers, multiple myeloma is driven to spread by only a subset of the myeloma cells within a patient's body, researchers at Dana-Farber Cancer Institute have found in a study presented at the annual meeting of the American Society of Hematology.

8 Dec 2014

Oral targeted drug shows encouraging activity in patients with relapsed or resistant AML

An oral targeted drug has shown encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML) - a poor-prognosis group with few options - report investigators from Dana-Farber Cancer Institute and M.D. Anderson Cancer Center.

8 Dec 2014

Two-drug combination may be effective for patients with higher-risk forms of MDS and AML

A phase two study that investigated the potential of the drugs azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two therapies in combination may be an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia.

8 Dec 2014

Baylor-led researchers identify gene linked to familial glioma

An international consortium of researchers led by Baylor College of Medicine has identified for the first time a gene associated with familial glioma (brain tumors that appear in two or more members of the same family) providing new support that certain people may be genetically predisposed to the disease.

8 Dec 2014

Adolescent and young adult patients with ALL fare better with high-intensity pediatric protocols

Results from a large, prospective clinical trial add to mounting evidence that adolescent and young adult patients--aged 16 to 39 with acute lymphoblastic leukemia (ALL)--tend to fare better when treated with high-intensity pediatric protocols than previous patients who were treated with standard adult regimens.

8 Dec 2014

New type of cancer therapy shows promise in patients with advanced leukemia

A new type of cancer therapy that targets an oncometabolite produced dramatic results in patients with advanced leukemia in an early-phase clinical trial. The study, led by Eytan M. Stein, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, was presented today at the 56th Annual Meeting of the American Society of Hematology.

8 Dec 2014

Medical Condition News

UC Berkeley study finds self-worth key to diagnoses of psychopathologies

Spark Therapeutics, Pfizer partner to develop SPK-FIX for potential treatment of hemophilia B

Henry Ford Hospital recruits patients to participate in brain cancer clinical trial

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

New fluorescence-imaging agent could improve diagnosis, guide surgeons during tumor removal

Daiichi Sankyo releases new formulation of LIXIANA 60 mg Tablets

Researchers report promising outcomes from clinical trial in patients with dyskeratosis congenita

Scientists discover new line of defence that cancer cells use to evade cell death

New advancement in biomedical research could help tackle diseases associated with ageing

Vitamin C may reduce exercise-induced bronchoconstriction and respiratory symptoms

Combination therapy benefits patients with acute myeloid leukemia

iTeos Therapeutics, Pfizer form strategic collaboration for cancer immunotherapeutics

Researchers gain new insights into potential treatment for Alzheimer's disease

Subsets of cells drive spread of multiple myeloma

Oral targeted drug shows encouraging activity in patients with relapsed or resistant AML

Two-drug combination may be effective for patients with higher-risk forms of MDS and AML

Baylor-led researchers identify gene linked to familial glioma

Adolescent and young adult patients with ALL fare better with high-intensity pediatric protocols

New type of cancer therapy shows promise in patients with advanced leukemia

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News